These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 2938865

  • 1. Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer.
    Bird CE, Masters V, Sterns EE, Clark AF.
    Clin Invest Med; 1985; 8(2):97-102. PubMed ID: 2938865
    [Abstract] [Full Text] [Related]

  • 2. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
    Levin J, Markham MJ, Greenwald ES, O'Connor JF, Zumoff B, Fukushima DK.
    Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
    [Abstract] [Full Text] [Related]

  • 3. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M, Jukić S, Ilić-Forko J, Babić D, Uzarević B, Petrovecki M, Suchanek E, Skrablin S, Dotlić S, Marusić M.
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [Abstract] [Full Text] [Related]

  • 4. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):110-5. PubMed ID: 16418513
    [Abstract] [Full Text] [Related]

  • 5. Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
    Bird CE, Masters V, Sterns EE, Clark AF.
    Cancer Res; 1982 Nov 18; 42(11):4797-800. PubMed ID: 6290048
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J.
    Clin Cancer Res; 1995 Mar 18; 1(3):287-94. PubMed ID: 9815984
    [Abstract] [Full Text] [Related]

  • 7. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Mar 18; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 8. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):595-602. PubMed ID: 15840882
    [Abstract] [Full Text] [Related]

  • 9. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro.
    Goldenberg GJ, Froese EK.
    Cancer Res; 1982 Dec 20; 42(12):5147-51. PubMed ID: 7139616
    [Abstract] [Full Text] [Related]

  • 10. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
    Bhatavdekar JM, Shah NG, Trivedi SN, Karelia NH.
    Neoplasma; 1987 Dec 20; 34(1):95-9. PubMed ID: 3104809
    [Abstract] [Full Text] [Related]

  • 11. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1856-65. PubMed ID: 15601642
    [Abstract] [Full Text] [Related]

  • 12. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
    Samojlik E, Veldhuis JD, Wells SA, Santen RJ.
    J Clin Invest; 1980 Mar 15; 65(3):602-12. PubMed ID: 6986409
    [Abstract] [Full Text] [Related]

  • 13. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
    Wilking N, Carlström K, Sköldefors H, Theve NO, Wallgren A.
    Acta Chir Scand; 1982 Mar 15; 148(4):345-9. PubMed ID: 6215811
    [Abstract] [Full Text] [Related]

  • 14. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR, Sutherland RL.
    Cancer Res; 1987 Oct 15; 47(20):5323-9. PubMed ID: 3652038
    [Abstract] [Full Text] [Related]

  • 15. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk.
    Yu H, Shu XO, Li BD, Dai Q, Gao YT, Jin F, Zheng W.
    Cancer Epidemiol Biomarkers Prev; 2003 Oct 15; 12(10):1067-73. PubMed ID: 14578144
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
    Kampa M, Nifli AP, Charalampopoulos I, Alexaki VI, Theodoropoulos PA, Stathopoulos EN, Gravanis A, Castanas E.
    Exp Cell Res; 2005 Jul 01; 307(1):41-51. PubMed ID: 15922725
    [Abstract] [Full Text] [Related]

  • 18. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC, Fritz NF, Tormey DC.
    Cancer Res; 1987 Jan 15; 47(2):624-30. PubMed ID: 3098415
    [Abstract] [Full Text] [Related]

  • 19. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z, Gardi J, Nyári T, Földesi I, Hajnal-Papp R, Ormándi K, Lázár G, Thurzó L, Schally AV.
    Int J Oncol; 2006 Jul 15; 29(1):193-200. PubMed ID: 16773200
    [Abstract] [Full Text] [Related]

  • 20. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.
    Clin Cancer Res; 2009 May 15; 15(10):3610-6. PubMed ID: 19401349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.